Lineage Cell Therapeutics Inc Capital Reinvestment Ratio
Lineage Cell Therapeutics Inc capital reinvestment ratio. Lineage Cell Therapeutics Inc (LCTX) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow ($21.90 Million) in capital expenditures ($46.00K). Check Lineage Cell Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Lineage Cell Therapeutics Inc (2022–2022)
Capital reinvestment ratio of Lineage Cell Therapeutics Inc from 2022 to 2022. This chart tracks Lineage Cell Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Also explore net asset growth rate of Lineage Cell Therapeutics Inc to track the company's year-over-year net asset growth rate.
Lineage Cell Therapeutics Inc Capital Reinvestment Ratio by Year (2022–2022)
Lineage Cell Therapeutics Inc capital reinvestment ratio by year from 2022 to 2022. For the full cash flow conversion analysis, see cash efficiency ratio of Lineage Cell Therapeutics Inc.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.39x | $1.06 Million | $413.00K | — |